Lanoxicaps Related Published Studies
Well-designed clinical trials related to Lanoxicaps (Digoxin)
The hemodynamic and pharmacokinetic interactions between chronic use of oral levosimendan and digoxin in patients with NYHA Classes II-III heart failure. [2008.08]
No effect of imidafenacin, a novel antimuscarinic drug, on digoxin pharmacokinetics in healthy subjects. [2008]
Intravenous and oral administration of amiodarone for the treatment of recent onset atrial fibrillation after digoxin administration. [2007.10.18]
Digoxin bioequivalence study: determination in human plasma by microparticle enzyme immunoassay. [2007.06]
Digoxin and reduction in mortality and hospitalization in geriatric heart failure: importance of low doses and low serum concentrations. [2007.03]
Verapamil versus digoxin and acute versus routine serial cardioversion for the improvement of rhythm control for persistent atrial fibrillation. [2006.09.05]
Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. [2006.08.01]
Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects. [2006.08]
Predictive power of an in vitro system to assess drug interactions of an antimuscarinic medication: a comparison of in vitro and in vivo drug-drug interaction studies of trospium chloride with digoxin. [2006.07]
Serum digoxin concentration and outcomes in women with heart failure: A bi-directional effect and a possible effect modification by ejection fraction. [2006.06]
Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. [2006.01]
Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. [2006.01]
Influence of coadministration on the pharmacokinetics of azimilide dihydrochloride and digoxin. [2005.07]
No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract. [2005.04]
Well-designed clinical trials possibly related to Lanoxicaps (Digoxin)
Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. [2008.09]
Treatment of heart failure with preserved systolic function. [2008.05]
Comparison of rate and rhythm control in hypertension patients with atrial fibrillation. [2008.05]
Mifepristone in second-trimester medical abortion: a randomized controlled trial. [2007.12]
Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. [2007.06]
Initial United States experience with the Paracor HeartNet myocardial constraint device for heart failure. [2007.01]
Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities. [2006.11]
Effects of a high dose intravenous bolus amiodarone in patients with atrial fibrillation and a rapid ventricular rate. [2006.06.07]
Effects of Kanlijian on exercise tolerance, quality of life, and frequency of heart failure aggravation in patients with chronic heart failure. [2006.06]
A hospital perspective on the cost-effectiveness of beta-blockade for prophylaxis of atrial fibrillation after cardiothoracic surgery. [2005.12]
Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). [2005.11.29]
A randomized controlled trial of magnesium sulfate, in addition to usual care, for rate control in atrial fibrillation. [2005.04]
Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review. [2005.04]
A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy. [2005.03.15]
Azimilide, a novel oral class III antiarrhythmic for both supraventricular and ventricular arrhythmias. [2005.02]
When should we discontinue antiarrhythmic therapy for atrial fibrillation after coronary artery bypass grafting? A prospective randomized study. [2005.02]
Other research related to Lanoxicaps (Digoxin)
Lack of a pharmacokinetic interaction between a new smoking cessation therapy, varenicline, and digoxin in adult smokers. [2008.11]
[Treatment of severe digoxin intoxication with antidote] [2008.10.13]
Absence of an effect of a single-dose deferasirox on the steady-state pharmacokinetics of digoxin. [2008.10]
Evaluation of the pharmacokinetics of digoxin in healthy subjects receiving etoricoxib. [2008.09.24]
Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. [2008.08]
Lack of a pharmacokinetic interaction between a new smoking cessation therapy, varenicline, and digoxin in adult smokers. [2008.07.26]
Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. [2008.07]
Declining public health burden of digoxin toxicity from 1991 to 2004. [2008.07]
Digoxin for the treatment of fetal congestive heart failure with sinus rhythm assessed by cardiovascular profile score. [2008.07]
Validation and application of a 96-well format solid-phase extraction and liquid chromatography-tandem mass spectrometry method for the quantitation of digoxin in human plasma. [2008.06.15]
Changes in digoxin pharmacokinetics treated with lipopolysaccharide in Wistar rats. [2008.06]
Can digoxin and sotalol therapy for fetal supraventricular tachycardia and hydrops be successful? A case report. [2008.05]
Rapid detection of oleander poisoning by Digoxin III, a new Digoxin assay: impact on serum Digoxin measurement. [2008.04]
Herbal supplements and therapeutic drug monitoring: focus on digoxin immunoassays and interactions with St. John's wort. [2008.04]
Effects of Pregnancy on CYP3A and P-glycoprotein Activities as Measured by Disposition of Midazolam and Digoxin: A University of Washington Specialized Center of Research Study. [2008.02.20]
Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: Comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. [2008.01.23]
Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. [2008.01.11]
National underuse of anti-thrombotic therapy in chronic atrial fibrillation identified from digoxin prescribing. [2007.11]
Digoxin and mortality in atrial fibrillation: a prospective cohort study. [2007.10]
Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers. [2007.08]
Population pharmacokinetic investigation of digoxin in Japanese neonates. [2007.08]
Effects of discontinuation of digoxin versus continuation at low serum digoxin concentrations in chronic heart failure. [2007.07.15]
Effect of NXY-059, a novel neuroprotectant, on the pharmacokinetics of a single dose of digoxin in healthy subjects. [2007.07]
Absence of an interaction between tigecycline and digoxin in healthy men. [2007.06]
Omeprazole-associated digoxin toxicity. [2007.04]
Fracture risk in patients treated with amiodarone or digoxin for cardiac arrhythmias: a nation-wide case-control study. [2007.04]
Plasma digoxin concentration fluctuations associated with timing of plasma sampling and amiodarone administration. [2007.03]
Effect of Goldenseal (Hydrastis canadensis) and Kava Kava (Piper methysticum) Supplementation on Digoxin Pharmacokinetics in Humans. [2007.02]
Impact of ABCB1 (MDR1) gene polymorphism and P-glycoprotein inhibitors on digoxin serum concentration in congestive heart failure patients. [2007.01]
Human intestinal P-glycoprotein activity estimated by the model substrate digoxin. [2007]
Age- and gender-specific incidence of hospitalisation for digoxin intoxication. [2007]
Successful treatment of propafenone, digoxin and warfarin overdosage with plasma exchange therapy and rifampicin. [2007]
Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux. [2007]
A method of determining the dose of digoxin for heart failure in the modern era. [2006.12.11]
Pharmacokinetics of digoxin cross-reacting substances in patients with acute yellow Oleander (Thevetia peruviana) poisoning, including the effect of activated charcoal. [2006.12]
[Cognitive impairment induced by digoxin intake in patients older than 65 years] [2006.10]
Is digoxin a drug of the past? [2006.09]
P-glycoprotein and an unstirred water layer barring digoxin absorption in the vascularly perfused rat small intestine preparation: induction studies with pregnenolone-16alpha-carbonitrile. [2006.09]
Digoxin therapy for heart failure: an update. [2006.08.15]
Cardio protective effect of glucose-insulin infusion on acute digoxin toxicity in rat. [2006.07.25]
Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference? [2006.07]
Suspected DLIS interference in the dimension DGNA digoxin assay method and the clinical application of the revised digoxin target range. [2006.06]
Digoxin use and digoxin toxicity in the post-DIG trial era. [2006.06]
What is the economic value of digoxin therapy in congestive heart failure patients? Results from the DIG trial. [2006.06]
Telithromycin-induced digoxin toxicity and electrocardiographic changes. [2006.06]
Effect of plantain on therapeutic drug monitoring of digoxin and thirteen other common drugs. [2006.05]
The safety of digoxin as a pharmacological treatment of atrial fibrillation. [2006.05]
The new enzyme-linked immunosorbent digoxin assay on the ADVIA Integrated Modular System is virtually free from oleander interference. [2006.04]
Evaluation of a sex-based difference in the pharmacokinetics of digoxin. [2006.01]
Mechanisms, manifestations, and management of digoxin toxicity in the modern era. [2006]
Therapeutic drug monitoring of digoxin: impact of endogenous and exogenous digoxin-like immunoreactive substances. [2006]
Successful treatment of oleander intoxication (cardiac glycosides) with digoxin-specific Fab antibody fragments in a 7-year-old child: case report and review of literature. [2005.12]
Effect of lasofoxifene on the pharmacokinetics of digoxin in healthy postmenopausal women. [2005.12]
Detection of cone dysfunction induced by digoxin in dogs by multicolor electroretinography. [2005.11]
Effect of exenatide on the steady-state pharmacokinetics of digoxin. [2005.09]
Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. [2005.08.02]
Dealing with DIG. A comprehensive review of digoxin and its therapeutic and toxic effects. [2005.08]
Wide QRS tachycardia caused by severe hyperkalaemia and digoxin intoxication. [2005.08]
Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. [2005.08]
Application of two-point assay of digoxin serum concentration in studying population pharmacokinetics in Egyptian pediatric patients with heart failure: does it make sense? [2005.07]
[Nerium oleander self poisoning treated with digoxin-specific antibodies] [2005.06]
Gastrointestinal symptoms as an important sign in premature newborns with severely increased S-digoxin. [2005.06]
Assessing the accuracy of a computerized decision support system for digoxin dosing in primary care: an observational study. [2005.06]
Comparison of target concentration intervention strategy with conventional dosing of digoxin. [2005.05]
Digoxin use is associated with increased platelet and endothelial cell activation in patients with nonvalvular atrial fibrillation. [2005.05]
Repercussions of digoxin, digitoxin and estradiol on the endometrial histomorphometry of oophorectomized mice. [2005.04]
New enzyme-linked immunosorbent digoxin assay on the ADVIA IMS 800i system is virtually free from interference of endogenous digoxin-like immunoreactive factors. [2005.04]
Relationship between loperamide-induced sedative effect and digoxin pharmacokinetics in healthy Japanese subjects. [2005.03]
Digoxin prescribing for heart failure in elderly residents of long-term care facilities. [2005.03]
[Combination therapy for fetal supraventricular tachycardia with flecainide and digoxin] [2005.02]
Digoxin inhibits neuroblastoma tumor growth in mice. [2005.01]
|
